MAPT and Alzheimer disease: This framework was used to examine neuropathological features, identify cell types and protein lesions in the hippocampus during different stages of AD, and assess the direct relationship between microglia and tau-related pathological changes in the CA1 hippocampal region in patients with AD [282].